Agilent Technologies Appoints Ron Nersesian President and COO
News Nov 15, 2012
Nersesian has been executive vice president and chief operating officer since November 2011.
Nersesian, 53, will continue to be responsible for Agilent's Chemical Analysis (CAG), Life Sciences (LSG), Electronic Measurement (EMG), and Agilent Order Fulfillment (AOF) businesses, with the presidents of those groups reporting to him. Nersesian will continue to report to William (Bill) Sullivan, who remains chief executive officer.
Nersesian first joined Hewlett-Packard Co., Agilent's predecessor company, in 1984. Since then he has served in various management positions, including president of the electronic measurement business from 2009 to 2011.
Nersesian holds a bachelor's degree in electrical engineering from Lehigh University and an MBA from New York University, Stern School of Business.
"Ron is an outstanding global business leader," said Sullivan. "He transformed EMG when he headed that business, resulting in record profitable growth across current and emerging markets."
"Over the past year as COO, Ron made significant strides in increasing the profitability of our life science and chemical analysis businesses even as we navigated through a difficult economy," said Sullivan.
Sullivan added, "Ron's appointment as president and COO is an opportunity for Agilent to further leverage the skills of an executive with an exceptional record of business growth, cost improvements and superior return on invested capital."
Genes Can Influence the Mutation, Activity of Nearby GenesNews
Study shows that a gene’s neighborhood can influence whether and how the activity of a gene changes.READ MORE
Brain Regions Implicated in Mental Disorders Influenced by Neanderthal GenesNews
Findings indicate that the more a person’s genome carries genetic vestiges of Neanderthals, the more certain parts of his or her brain and skull resemble those of humans’ evolutionary cousins that went extinct 40,000 years ago.READ MORE
Ingestible Drug-Delivery Materials May Improve Patient Treatment ComplianceNews
Hydrogel-based capsules could expand and reside in the GI tract for days, slowly releasing medication.READ MORE
Comments | 0 ADD COMMENT
Like what you just read? You can find similar content on the communities below.Cell Science Diagnostics Drug Discovery Genomics Research Informatics & Automation Proteomics & Metabolomics
To personalize the content you see on Technology Networks homepage, Log In or Subscribe for FreeLOGIN SUBSCRIBE FOR FREE
International Conference on Genomics and Pharmacogenomics
Jul 18 - Jul 19, 2018
International Conference and Exhibition on Nanomedicine and Nanotechnology
Nov 23 - Nov 24, 2017